The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Osteoporosis Drugs Show Promise in Therapy Pipeline

New Osteoporosis Drugs Show Promise in Therapy Pipeline

June 1, 2014 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

One measure of bone strength is cortical thickness, and this increased with use of odanacatib as well, Dr. Edwards said.

You Might Also Like
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
Explore This Issue
June 2014
Also By This Author
  • Treatments for Scleroderma with Gastrointestinal Involvement Address Symptoms

The results over five years, shown in a Phase 2 trial of postmenopausal women, were even more impressive.2 At the lumbar spine, there was an increase of 11.9% in bone mineral density. In the case of total hip, it was about 6%.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“It’s very substantial; it’s not something that you’re going to miss,” she said.

Another plus was the patients’ response rate. “Most of the patients responded; there was not a large number of nonresponders,” Dr. Edwards said. “We tend to see about 4–5% of patients not responding to therapy. Here that was not an issue.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The number of adverse events and discontinuations due to adverse events has been about the same as those on placebo.

The Promise

“So we have a drug that is an antiresorptive, that does not impair bone formation, but definitely shows effectiveness in inhibiting bone resorption,” Dr. Edwards said. “It increases bone mass. It increases volumetric bone mass. It increases biomechanical strength of the bone. It increases cortical thickness, all of which are elements that contribute to bone strength. So it seems fairly favorable.”

Before it can gain FDA approval, the investigators will have to show the drug prevents vertebral fractures, which has not yet been demonstrated, she said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Romosozumab

Another promising osteoporosis agent, Dr. Edwards said, is the monoclonal antibody romosozumab that targets sclerostin, a protein in osteocytes whose main function is to inhibit bone formation.

A one-year study has shown increases in volumetric bone density at the spine and hip in patients on romosozumab. Like odanacatib, this drug has not yet been shown to prevent fractures, which will be a requirement before gaining FDA approval, Dr. Edwards said.

“It is very welcome to have a second anabolic agent,” Dr. Edwards said, “although this one will likely only be used for a year at a time [because] it loses some efficacy after 12 months. It opens up a new generation of drugs that we can consider for our patients.”


Thomas R. Collins is a freelance medical writer based in Florida.

References

  1. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242–251.
  2. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251–2258.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates Tagged With: Beatrice Edwards, Biologics, cathepsin-K inhibitor, Collins, drug, odanacatib, Osteoporosis, patient care, rheumatologist, romosozumabIssue: June 2014

You Might Also Like:
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.